Skip to content

Press

Portfolio-Press Releases
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
February 15, 2024 Feb 15, 2024
Portfolio-Media Coverage
JPM24: ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity
January 17, 2024 Jan 17, 2024 Fierce Biotech
Portfolio-Media Coverage
The Therapeutic Areas that Stood Out in BioSpace’s NextGen Class of 2024
January 8, 2024 Jan 8, 2024 BioSpace
BLV-Press Releases
Bioluminescence Ventures Reveals Partners and Investment Management Team
January 5, 2024 Jan 5, 2024
Portfolio-Media Coverage
ReCode doses first subject in Phase I primary ciliary dyskinesia trial
January 4, 2024 Jan 4, 2024 Clinical Trials Arena
Portfolio-Media Coverage
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
January 3, 2024 Jan 3, 2024 BioSpace
Portfolio-Media Coverage
Oral SBMA therapy shows safety and tolerability in Phase 1 trial
November 15, 2023 Nov 15, 2023 SMA News Today
Portfolio-Press Releases
BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program
November 8, 2023 Nov 8, 2023
BLV-Media Coverage
Bioluminescence Ventures: Next-Generation Medicine Firm Emerges With $477 Million Fund
November 6, 2023 Nov 6, 2023 Pulse 2.0
Portfolio-Press Releases
Nido Biosciences Presents Clinical Data Supporting the Continued Development of NIDO-361 in SBMA Patients at the 2023 International Kennedy’s Disease Patient Conference
November 5, 2023 Nov 5, 2023